E1WL34.SA Edwards Lifesciences Corporation
- Market cap
- BRL 241B
- P/E
- 47.1x
- P/B
- 4.55x
- ROE
- 11.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is E1WL34.SA undervalued?
Graham numberThe Graham number of Edwards Lifesciences Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Edwards Lifesciences Corporation fundamental analysis
No fundamental analysis for Edwards Lifesciences Corporation yet.
Edwards Lifesciences Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The…
Full company profileEdwards Lifesciences Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Edwards Lifesciences Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 3.72B | 4.35B | 4.39B | 5.23B | 4.46B | 5.01B | 5.44B | 6.07B | 6.78B |
| Gross Profit | 2.78B | 3.23B | 3.31B | 3.98B | 3.74B | 4.03B | 4.32B | 4.73B | 5.27B |
| Operating Income | 1.07B | 1.24B | 1.32B | 1.59B | 1.50B | 1.31B | 1.43B | 1.12B | 2.07B |
| EBITDA | 869M | 1.28B | 1.04B | 1.86B | 1.68B | 1.53B | 1.72B | 1.45B | 2.24B |
| Net Income | 722M | 1.05B | 823M | 1.50B | 1.52B | 1.40B | 4.17B | 1.07B | 1.25B |
| EPS | 1.16 | 1.67 | 1.32 | 2.41 | 2.50 | 2.33 | 7.09 | 1.85 | 2.16 |
| Balance Sheet | |||||||||
| Total Assets | 5.32B | 6.49B | 7.24B | 8.50B | 8.29B | 9.36B | 13.1B | 13.7B | 13.9B |
| Total Liabilities | 2.18B | 2.34B | 2.66B | 2.67B | 2.49B | 2.64B | 2.99B | 3.36B | 3.14B |
| Shareholders' Equity | 3.14B | 4.15B | 4.57B | 5.84B | 5.81B | 6.65B | 10.00B | 10.3B | 10.6B |
| Cash & Short-term Investments | 714M | 1.18B | 1.40B | 1.47B | 1.22B | 1.64B | 3.98B | 4.23B | 2.91B |
| Cash Flow | |||||||||
| Operating Cash Flow | 927M | 1.18B | 1.05B | 1.73B | 1.22B | 896M | 542M | 1.60B | 1.39B |
| Capital Expenditure | 239M | 254M | 407M | 326M | 265M | 266M | 282M | 260M | 264M |
| Free Cash Flow | 685M | 901M | 647M | 1.40B | 953M | 630M | 260M | 1.34B | 1.13B |
| Ratios | |||||||||
| ROE | 23.0% | 25.2% | 18.0% | 25.8% | 26.2% | 21.1% | 41.8% | 10.4% | 11.7% |
| ROA | 13.6% | 16.1% | 11.4% | 17.7% | 18.4% | 15.0% | 32.0% | 7.8% | 9.0% |
| Net Profit Margin | 19.4% | 24.1% | 18.8% | 28.7% | 34.1% | 28.0% | 76.7% | 17.7% | 18.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Edwards Lifesciences Corporation dividends
Edwards Lifesciences Corporation has not paid dividends in the last 8 fiscal years.
Last stock split: 3:1 on Jun 1, 2020.
Who owns Edwards Lifesciences Corporation
Ownership data of Edwards Lifesciences Corporation is not available yet.
Edwards Lifesciences Corporation company profile
- Company name
- Edwards Lifesciences Corporation
- Ticker
- E1WL34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 16,000
- Fiscal year end
- December
- Address
- One Edwards Way, Irvine, CA, United States, 92614
- Phone
- 949 250 2500
- Website
- edwards.com
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation management
10- Mr. Bernard J. ZovighianCEO & Director · born 1968
- Mr. Donald E. Bobo Jr.Corporate Vice President of Strategy & Corporate Development · born 1962
- Mr. Daveen ChopraCorporate Vice President of Transcatheter Mitral & Tricuspid Therapies · born 1979
- Ms. Annette Maria BrulsCorporate Vice President of EMEA, Canada, & Latin America · born 1971
- Ms. Theodora MistrasCorporate VP & CFO · born 1982
- Mr. Joseph NuzzoleseCorporate Vice President of Global Operations & Quality
- Mr. Andrew M. DahlPrincipal Accounting Officer, Senior VP & Corporate Controller · born 1978
- Dr. Todd Brinton FACC, M.D.Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer
- Mr. Snehashish SarkarSenior VP and Chief Information & Digital Officer · born 1975
- Mr. Mark D. PetersonCorporate VP & General Counsel · born 1963